| lncRNA name in article | Virus & Strain Name | Dosage & Time point | Cell line | Experiment Type | Fold change | Expression | P-value | Differential expression quantification method | Statistical method | Year | PubMed ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EGO | Human immunodeficiency virus type 1 (VSV-G-pseudotyped HIV-1 NL4-3) | MOI=Not provided;
72 hr |
MT4Human T cell line | qPCR | 3.8 | Upregulation | p < 0.05 | Disease-related Human LncRNA Profiler (System Biosciences) | Not provided | 2013 | 23362321 |
| EGOT | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
A-549 Human adenocarcinomic alveolar basal epithelial cells | RNA-Seq | 4.114878977 | Upregulation | 1.52E-06 | student's t test | 2020 | 32416070 | |
| EGOT | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
Calu-3 Human adenocarcinomic lung epithelialcells | RNA-Seq | 9.694523571 | Upregulation | 7.89E-63 | student's t test | 2020 | 32416070 |
* MOI :Multiplicity of infection , TCID :Tissue Culture Infectious Dose